Treatment-Resistant Depression: A Psychiatry Perspective on Pathophysiological Mechanisms, Biomarkers, and Novel Therapeutic Frontiers
Muhammad Bilal Akram, Ali Sher, Areena Fatima, Ayesha Arif, Dua Fozan Sareshwala, Zahra Nawaz, Umair Khalil
INNOVAPATH June 22, 2026 DOI: 10.63501/54mphj57 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Perspective Peer reviewed |
|---|---|
| Population | Patients with TRD |
| Topics | Depression |
| Keywords | Perspective graphical Psychosocial Identification biology Depression economics Clinical practice Public health Psychotherapist Disease Therapeutic approach Medline |
| Key points | Proposes that integrating advances in understanding TRD mechanisms, biomarkers, and emerging therapies may enable more personalized and effective management. |
Abstract
Treatment-resistant depression (TRD) represents a major clinical and public health challenge, affecting a substantial proportion of patients with major depressive disorder who fail to achieve remission despite adequate pharmacotherapy. Emerging evidence suggests that TRD is a heterogeneous condition driven by complex interactions among neurobiological, inflammatory, and psychosocial factors. Advances in understanding pathophysiological mechanisms—including neuroinflammation, synaptic dysfunction, and neuroendocrine dysregulation—have facilitated the identification of potential biomarkers and the development of novel therapeutic strategies. This perspective explores current insights into the mechanisms underlying TRD, highlights promising biomarkers for diagnosis and treatment stratification, and discusses emerging therapeutic frontiers such as rapid-acting antidepressants, neuromodulation, and psychedelic-assisted therapy. Integrating these advances into clinical practice may enable a more personalized and effective approach to managing TRD.